Last reviewed · How we verify
Miricorilant 100 mg
At a glance
| Generic name | Miricorilant 100 mg |
|---|---|
| Also known as | CORT118335 |
| Sponsor | Corcept Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Alanine aminotransferase increased
- Nausea
- Aspartate aminotransferase increased
- Akathisia
- Orthostatic hypotension
- Anaemia
- Somnolence
Key clinical trials
- Evaluation of Miricorilant on Liver Fat in Patients With MASLD (PHASE1)
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) (PHASE2)
- Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects (PHASE1)
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications (PHASE2)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) (PHASE1)
- Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |